|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | High levels of circulating GM-CSF^(+) CD4^(+) T cells are predictive of poor outcomes in sepsis patients: a prospective cohort study显示文摘Granulocyte colony-stimulating factor(GM-CSF),produced by CD4^(+)T cells,has recently been implicated in the pathogenesis of inflammatory diseases,such as multiple sclerosis and juvenile arthritis.However,the role of GM-CSF-producing CD4^(+)T cells in sepsis remains unknown.This study reports peripheral changes in GM-CSF-producing CD4^(+)T cells in septic patients and the possible underlying mechanism by which GM-CSF influences the outcome of sepsis.Forty-three septic patients,20 SIRS patients,and 20 healthy controls were enrolled in this study and followed for 28 days to assess mortality.We measured the peripheral frequency of GM-CSF^(+)CD4^(+)T cells and recorded their associated relationship with disease progression.Our data demonstrated that peripheral GM-CSF-producing CD4^(+)T cells were significantly higher in septic patients than in both SIRS patients and healthy controls.These cells exhibit a memory phenotype and impaired IFN-γ-secreting capacity in sepsis patients.Using a receiver operating curve analysis with 8.01%as a cut-off point,the percentage of GM-CSF^(+)CD4^(+)T cells could predict the outcome of septic patients.Combined with the increase in GM-CSF-producing CD4^(+)T cells,inflammatory cytokines IL-1βand IL-6 were also upregulated.Using an in vitro neutrophil model,we found that GM-CSF inhibited C3aR expression,while inducing IL-8 production.Furthermore,this effect was transferrable in plasma from sepsis patients and was attenuated by inhibition of GM-CSF using an anti-GM-CSF antibody.These results indicate that GM-CSF-producing CD4^(+)T cells may serve as a marker of sepsis severity.Thus,targeting GM-CSF overproduction may benefit sepsis patients. | Huihuang Huang Siyu Wang Tianjun Jiang Rong Fan Zheng Zhang Jinsong Mu Ke Li Yonggang Wang Lei Jin Fang Lin Jie Xia Lijian Sun Biao Xu Chengcheng Ji Jing Chen Juan Chang Bo Tu Bing Song Chao Zhang Fu-Sheng Wang Ruonan Xu | 2019 | Cellular & Molecular Immunology2019，16，6： | 6 |
| 2 | Non-permanent Pole-to-pole Fault Restoration Strategy for Flexible DC Distribution Network显示文摘As the structures of multiple branch lines(MBLs)will be widely applied in the future flexible DC distribution network,there is a urgent need for improving system reliability by tackling the frequent non-permanent pole-to-pole(P-P)fault on distribution lines.A novel fault restoration strategy based on local information is proposed to solve this issue.The strategy firstly splits a double-ended power supply network into two single-ended power supply networks through the timing difference characteristics of a hybrid direct current circuit breaker(HDCCB)entering the recloser.Then,a method based on the characteristic of the transient energy of fault current is proposed to screen the faulty branch line in each single-ended power supply network.Also,a four-terminal flexible DC distribution network with MBLs is constructed on PSCAD to demonstrate the efficacy of the proposed strategy.Various factors such as noise,fault location,and DC arc equivalent resistance are considered in the simulation model for testing.Test results prove that the proposed strategy for fault restoration is effective,and features high performance and scalability. | Zainan Li Jiandong Duan Wenchao Lu Xiaotong Du Wei Yang Siyu Tu | 2021 | Journal of Modern Power Systems and Clean Energy2021，9，6： | 1 |
| 3 | Human umbilical cord mesenchymal stem cell transfusion in immune non-responders with AIDS:a multicenter randomized controlled trial显示文摘We examined the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC)infusion for immune nonresponder(INR)patients with chronic HIV-1 infection,who represent an unmet medical need even in the era of efficient antiretroviral therapy(ART).Seventy-two INR patients with HIV were enrolled in this phase II randomized,double-blinded,multicenter,placebo-controlled,dose-determination trial(NCT01213186)from May 2013 to March 2016.They were assigned to receive high-dose(1.5 x 106/kg body weight)or low-dose(0.5 x 106/kg body weight)hUC-MSC,or placebo.Their clinical and immunological parameters were monitored during the 96-week follow-up study.We found that hUC-MSC treatment was safe and well-tolerated.Compared with baseline,there was a statistical increase in CD4+T counts in the high-dose(P<0.001)and low-dose(P<0.001)groups after 48-week treatment,but no change was observed in the control group.Kaplan-Meier analysis revealed a higher cumulative probability of achieving an immunological response in the low-dose group compared with the control group(95.8%vs.70.8%,P=0.00A).However,no significant changes in CD4/CD84-T counts and CD4/CD8 ratios were observed among the three groups.In summary,hUC-MSC treatment is safe.However,the therapeutic efficacy of hUC-MSC treatment to improve the immune reconstitution in INR patients still needs to be further investigated in a large cohort study. | Lifeng Wang Zheng Zhang Ruonan Xu Xicheng Wang Zhanjun Shu Xiejie Chen Siyu Wang Jiaye Liu Yuanyuan Li Li Wang Mi Zhang Wei Yang Ying Wang Huihuang Huang Bo Tu Zhiwei Liang Linghua Li Jingxin Li Yuying Hou Ming Shi Fu-Sheng Wang | 2021 | Signal Transduction and Targeted Therapy2021，6，7： | 0 |
| 4 | A systematic assessment of hydroxyapatite nanoparticles used in the treatment of melanoma显示文摘Nano Research volume 13,pages2106–2117(2020)Cite this article 106 Accesses 1 Altmetric Metrics details Abstract Melanoma is a highly malignant skin tumor which is prone to recurrence and metastasis.Hydroxyapatite nanoparticles(nHAPs)were reported to possess a suppressive effect on proliferation of various tumor cells in vitro.This study aimed to assess in vitro and in vivo anti-tumor ability and biosafety of the nHAPs used in the treatment of melanoma.Three types of nHAPs with different morphology and crystallinity were synthesized.In vitro cell viability and proliferation studies demonstrated that all three types of nHAPs can inhibit viability and proliferation of A375 and SK-MEL-28 melanoma cells in a concentration-dependent manner.In addition,the rod-shape nHAPs with a crystallinity of 45.60%had the most prominent suppressive effect on the two melanoma cells tested.An important positive regulator of G1/S phase transition in cell cycle,Cyclin D1 protein,was reduced by nHAPs treatment in vivo.We further discovered that the migration ability of the nHAPs treated melanoma cells was greatly decreased.RNA sequencing result revealed that melanoma metastasis related genes were down-regulated by nHAPs,including MMP2,MMP14,ITGA9,ITGB3,ITGB4 and S100B.High concentration of nHAPs treatment in melanoma-bearing nude mice showed a strong inhibitory effect on tumor size and weight.Most importantly,hemolysis,electrolyte disturbance or inflammation response was not discovered in the experimental animals from nHAPs treated groups.We proved that the nHAPs synthesized in the current study has a selective effect to suppress melanoma tumor proliferation and was safe with regard to normal cells and tissue. | Zhongtao Li Jiaoqing Tang Hongfeng Wu Zhixin Ling Siyu Chen Yong Zhou Bo Guo Xiao Yang Xiangdong Zhu Lin Wang Chongqi Tu Xingdong Zhang | 2020 | Nano Research2020，13，8： | 0 |
| 5 | Clinical Epidemiology,Illness Profiles,and the Implication of COVID-19 Before and After the Nationwide Omicron Outbreak During the Winter of 2022显示文摘China.In this study,we aimed to investigate the clinical characteristics and outcomes of patients with coronavirus disease 2019(COVID-19)in the Beijing region.Methods:In this retrospective study,we enrolled inpatients admitted for COVID-19 in the Fifth Medical Center of Chinese PLA General Hospital in Beijing between November 10,2022,and January 30,2023.Demographic and clinical features and treatment outcomeswere comprehensively analyzed.We used logistic regression and linear regression analyses to explore the risk factors associated with disease severity and time of nucleic acid conversion,respectively.Results:A total of 1010 hospitalized patients with COVID-19 were enrolled.The median age was 43.0 years(interquartile range,28.0–63.0),and patients aged<60 years and≥60 years comprised 71.2%and 28.8%of total included patients,respectively.The clinical classification of mild(74.6%,753/1010),moderate(21.0%,212/1010),severe(2.7%,27/1010),and unidentified(1.8%,18/1010)was separately recorded;1005 patients were discharged,and 5 patients died in the hospital.The outbreak of the emerging epidemic witnessed an evident increase in the proportion of moderate(42.9%vs.16.4%)and severe(10.3%vs.1.1%)cases after December 7,2022.Patients with a moderate/severe classification had higher levels of procalcitonin,IL-6,serum ferritin,C-reactive protein,lactic dehydrogenase,serum urea nitrogen,and D-dimer and lower counts of CD4+T,CD8+T,and B cells(all P<0.001).Multivariable regression analysis revealed that increased odds of disease severity were associated with the following factors:age≥60 years,IL-6>7 pg/mL,lactic dehydrogenase level>245 U/L,cough,and fever at admission.Age≥80 years and chronic lung diseasewere independent risk factors in the nonmild group in elderly patients.In addition,the duration for nucleic acid to turn negativewas approximately 5.0 d(interquartile range,3.0–7.0).Prolonged time of nucleic acid conversion was associated with age≥60 years,serum urea nitrogen level>8.2 mmol/L,neutrophil count>7×10^(9)/L,and the presence of a chronic lung disease or carcinoma.Finally,unvaccinated patients accounted for 37.3%of enrolled patients;children and the elder people accounted for approximately half of that.The univariable analysis found that booster doses reduced disease severity and shortened the time of nucleic acid conversion in elderly patients.Conclusions:The outbreak ofOmicron rapidly increased the number of patientswith COVID-19 in Beijing.In elderly patients,booster doses may reduce disease severity and shorten the time of nucleic acid conversion.Healthcare systems should be optimized before an emerging epidemic outbreak. | Yuming Guo Zhe Xu Wen-Xin Wang Cheng Zhen Jinhua Hu Jinsong Mu Chengcheng Ji Xin Yuan Ruonan Xu Lei Huang Lei Shi Fanping Meng Junliang Fu Shuangnan Zhou Siyu Wang Fengyi Li Bo Tu Dawei Zhang Huihuang Huang Yufeng Mao Wen Xu Chao Zhang Xiuying Mu Jun Zhao Bo Jin Haibin Su Yinying Lu Yongqian Cheng Dong Ji Shaoli You Jinghui Dong Changchun Liu Mengmeng Zhang Yuanyuan Li Tianjun Jiang Yonggang Li Fu-Sheng Wang | 2023 | Infectious Diseases & Immunity2023，3，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员